To investigate the efficacy and safety of humanized CD19-specific chimeric antigen receptor T cells(hCART19s)in treating children and young adults with relapsed/refractory acute lymphoblastic leukemia(R/R ALL)and to analyze relevant factors affecting its curative effect and prognosis. Here, CD19 is linked to acute lymphoblastic leukemia.